{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:10Z","timestamp":1753891870497,"version":"3.41.2"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T00:00:00Z","timestamp":1665619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Although patients with light chain amyloidosis (AL) may present with co-deposition of amyloid and immune complexes (ICs) in renal biopsies, data on clinical characteristics and prognostic value of renal IC deposition are limited. A total of 73 patients with AL amyloidosis who were newly diagnosed by renal biopsy in Xijing Hospital (Xi\u2019an, China) were divided into two groups (IC and non-IC groups). As a result, renal IC deposition was found in 26% of patients. Patients with IC deposition were associated with more urinary protein excretion and lower serum albumin. Notably, patients in the non-IC group achieved higher hematological overall response rate (81.5% <jats:italic>vs.<\/jats:italic> 47.4%, <jats:italic>p<\/jats:italic> = 0.007) and \u2265VGPR rate (75.9% <jats:italic>vs.<\/jats:italic> 39.8%, <jats:italic>p<\/jats:italic> = 0.004) compared with those in IC group. Renal response rate was also higher in the non-IC group (63% <jats:italic>vs.<\/jats:italic> 31.6%, <jats:italic>p<\/jats:italic> = 0.031). With the median follow-up time of 19 months, a significantly worse overall survival was observed in patients with the IC group as compared with those without renal IC deposition in the Kaplan\u2013Meier analysis (<jats:italic>p<\/jats:italic> = 0.036). Further multivariate analysis demonstrated that renal immune complex deposition was associated with worse overall survival in patients with AL amyloidosis (HR 5.927, 95% CI 2.148\u201316.356, p = 0.001).<\/jats:p>","DOI":"10.3389\/fonc.2022.949702","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T10:16:01Z","timestamp":1665656161000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical characteristics and prognostic value of renal immune complex deposition in patients with light chain amyloidosis"],"prefix":"10.3389","volume":"12","author":[{"given":"Jipeng","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meilan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boyong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei-Feng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiren","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1046\/j.1523-1755.2002.00085.x","article-title":"Immunoglobulin light chain amyloidosis and the kidney","volume":"61","author":"Gertz","year":"2002","journal-title":"Kidney Int"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"Al (Light-chain) cardiac amyloidosis: A review of diagnosis and therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2010.1.287","article-title":"Systemic light-chain amyloidosis: Advances in diagnosis, prognosis, and therapy","volume":"2010","author":"Cohen","year":"2010","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.02740806","article-title":"Light-chain (Al) amyloidosis: Diagnosis and treatment","volume":"1","author":"Sanchorawala","year":"2006","journal-title":"Clin J Am Soc Nephrology: CJASN"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in Al amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-882159","article-title":"Al Amyloidosis cardiac staging updated using bnp","volume":"133","author":"Venner","year":"2019","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(03)13396-x","article-title":"Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins","volume":"361","author":"Dispenzieri","year":"2003","journal-title":"Lancet (London England)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2004.03.029","article-title":"Serum cardiac troponins and n-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-267708","article-title":"Assessment of disease severity and outcome in patients with systemic light-chain amyloidosis by the high-sensitivity troponin T assay","volume":"116","author":"Kristen","year":"2010","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-06-858951","article-title":"Development and validation of a survival staging system incorporating bnp in patients with light chain amyloidosis","volume":"133","author":"Lilleness","year":"2019","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12968-019-0564-1","article-title":"Prognostic value of novel imaging parameters derived from standard cardiovascular magnetic resonance in high risk patients with systemic light chain amyloidosis","volume":"21","author":"Arenja","year":"2019","journal-title":"J Cardiovasc Magn Reson"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205336","article-title":"Performance analysis of Al amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia","volume":"104","author":"Dittrich","year":"2019","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-767475","article-title":"Al Amyloidosis patients with low amyloidogenic free light chain levels at first diagnosis have an excellent prognosis","volume":"130","author":"Dittrich","year":"2017","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-07-2922","article-title":"Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation","volume":"107","author":"Dispenzieri","year":"2006","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.50.8499","article-title":"Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis","volume":"31","author":"Kourelis","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/13506129.2018.1443439","article-title":"Bone marrow plasma cell infiltration in light chain amyloidosis: Impact on organ involvement and outcome","volume":"25","author":"Tovar","year":"2018","journal-title":"Amyloid: Int J Exp Clin investigation: Off J Int Soc Amyloidosis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1038\/s41375-020-0993-8","article-title":"Correction: Bone marrow plasma cells 20% or greater discriminate presentation, response, and survival in Al amyloidosis","volume":"34","author":"Muchtar","year":"2020","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13369","article-title":"Translocation T (And survival of patients with light chain (Al) amyloidosis","volume":"94","author":"Bryce","year":"2009","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0060-x","article-title":"Depth of organ response in Al amyloidosis is associated with improved survival: Grading the organ response criteria","volume":"32","author":"Muchtar","year":"2018","journal-title":"Leukemia"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2019.1582486","article-title":"Depth of organ response in Al amyloidosis is associated with improved survival: New proposed organ response criteria","volume":"26","author":"Muchtar","year":"2019","journal-title":"Amyloid: Int J Exp Clin investigation: Off J Int Soc Amyloidosis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26569","article-title":"Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment","volume":"97","author":"Gertz","year":"2022","journal-title":"Am J Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2020.06.029","article-title":"Amyloid typing by mass spectrometry in clinical practice: A comprehensive review of 16,175 samples","volume":"95","author":"Dasari","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.2008.72","article-title":"Immunoglobulin derived depositions in the nervous system: Novel mass spectrometry application for protein characterization in formalin-fixed tissues","volume":"88","author":"Rodriguez","year":"2008","journal-title":"Lab investigation; J Tech Methods Pathol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.108","article-title":"Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis","volume":"82","author":"Sethi","year":"2012","journal-title":"Kidney Int"},{"key":"B27","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1365-2141.2004.04970.x","article-title":"Guidelines on the diagnosis and management of Al amyloidosis","volume":"125","year":"2004","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: Impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic amyloidosis recognition, prognosis, and therapy: A systematic review","volume":"324","author":"Gertz","year":"2020","journal-title":"Jama"},{"key":"B30","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1159\/000508287","article-title":"Prognosis and staging of Al amyloidosis","volume":"143","author":"Dittrich","year":"2020","journal-title":"Acta Haematologica"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.01285","article-title":"Bortezomib, melphalan, and dexamethasone for light-chain amyloidosis","volume":"38","author":"Kastritis","year":"2020","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-473066","article-title":"A European collaborative study of treatment outcomes in 346 patients with cardiac stage iii Al amyloidosis","volume":"121","author":"Wechalekar","year":"2013","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.11.7071","article-title":"Diagnostic and therapeutic potential of amyloid-reactive igg antibodies contained in human sera","volume":"176","author":"O\u2019Nuallain","year":"2006","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/rhu.0000000000000207","article-title":"Clinical and pathological study on patients with primary antineutrophil cytoplasmic autoantibody-associated vasculitis with renal immune complex deposition","volume":"21","author":"Li","year":"2015","journal-title":"J Clin Rheumatol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1046\/j.1365-2141.2003.04433.x","article-title":"Outcome in systemic Al amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy","volume":"122","author":"Lachmann","year":"2003","journal-title":"Br J haematology"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12973","article-title":"Lenalidomide and dexamethasone for systemic Al amyloidosis following prior treatment with thalidomide or bortezomib regimens","volume":"166","author":"Mahmood","year":"2014","journal-title":"Br J Haematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.5858\/133.2.283","article-title":"Focal glomerular immune complex deposition: Possible role of periglomerular Fibrosis\/Atubular glomeruli","volume":"133","author":"Satoskar","year":"2009","journal-title":"Arch Pathol Lab Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.949702\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T10:16:04Z","timestamp":1665656164000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.949702\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,13]]},"references-count":38,"alternative-id":["10.3389\/fonc.2022.949702"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.949702","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2022,10,13]]},"article-number":"949702"}}